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Gene editing tools are essential for uncovering how genesmediate normal brain–behavior
relationships and contribute to neurodegenerative and neuropsychiatric disorders.
Recent progress in gene editing technology now allows neuroscientists unprecedented
access to edit the genome efficiently. Although many important tools have been
developed, here we focus on approaches that allow for rapid gene editing in the adult
nervous system, particularly CRISPR/Cas9 and anti-sense nucleotide-based techniques.
CRISPR/Cas9 is a flexible gene editing tool, allowing the genome to be manipulated
in diverse ways. For instance, CRISPR/Cas9 has been successfully used to knockout
genes, knock-in mutations, overexpress or inhibit gene activity, and provide scaffolding
for recruiting specific epigenetic regulators to individual genes and gene regions.
Moreover, the CRISPR/Cas9 system may be modified to target multiple genes at one
time, affording simultaneous inhibition and overexpression of distinct genetic targets.
Although many of the more advanced applications of CRISPR/Cas9 have not been
applied to the nervous system, the toolbox is widely accessible, such that it is poised
to help advance neuroscience. Anti-sense nucleotide-based technologies can be used
to rapidly knockdown genes in the brain. Themain advantage of anti-sense based tools is
their simplicity, allowing for rapid gene delivery with minimal technical expertise. Here, we
describe the main applications and functions of each of these systems with an emphasis
on their many potential applications in neuroscience laboratories.
Keywords: CRISPR/Cas9, anti-sense nucleotides, Morpholino, gene editing, brain, CNS, knockdown,
overexpression
Genes exert powerful effects on human behavior, and maladaptive alterations in gene function
are implicated in a diverse range of neurological and neuropsychiatric disorders. Uncovering the
mechanisms by which genes influence behavior is an important goal of neuroscience. In addition
to elucidating the roles genes play in normal regulation of cognitive and affective functions,
this understanding is key for developing novel and effective therapeutic interventions for brain
disorders (Mamdani et al., 2013; Bae et al., 2015; Szyf, 2015). Achieving this goal requires the
ability to manipulate (both increase and decrease) gene expression. The regulation of gene function
in the brain is highly dynamic and may be different across brain regions (Zovkic et al., 2013;
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Walters and Zovkic, 2015). Therefore, manipulating gene
function in the brain poses particular challenges, in that gene
manipulations should be temporally and spatially specific.
Many gene editing tools have been developed to address
these challenges. Here, we will discuss some current gene
editing tools that hold particular promise for application in
neuroscience. In particular, we will focus on the CRISPR/Cas9
system, which allows for a wide range of gene editing applications
through an unprecedented degree of flexibility and user-friendly
engineering technology. In addition, we will discuss the latest
advances in anti-sense oligonucleotide approaches for gene
knockdown because of their high level of accessibility and ease
with which they can be applied across neuroscience laboratories
with minimal requirements for in-house design.
THE EVOLUTION OF GENE EDITING
TOOLS
Perhaps the earliest efforts at manipulating gene function to
understand their role in behavior were pharmacological. Drugs
have been used as protein agonists or antagonists to provide a
temporally restricted (and regionally restricted, if microinjected
into discrete brain regions) method of manipulating the function
of a protein. While drugs offer good temporal precision, they also
have some drawbacks, such as off-target effects. In addition, it is
difficult to design new drugs to target new proteins of interest.
The development of knockout transgenic mice, which provided
the ability to target any gene of interest (Hanahan et al., 2007), has
allowed researchers to specifically manipulate a variety of genes.
The first knockout transgenic strategy used germline knockout
mutations that resulted in transgenic mice in which the target
gene was either deleted or overexpressed in all tissues, typically
throughout development. The use of tissue-specific promoters,
such as the brain-specific t9 (Bessis et al., 1997) or α CaMKII
promoter (Mayford et al., 1996), to drive transgene expression
in particular tissue types afforded some regional specificity of
overexpression. Nevertheless, the temporal specificity was still
lacking, as transgene expression was tied to the transcriptional
onset of the promoter driving its expression. Moreover, these
transgenic approaches required both considerable time and effort
to generate and breed.
The next generation of transgenic strategies involved tissue-
specific gene knockout. This was achieved through the use of Cre-
LoxP system (Gu et al., 1994). Cre recombinase is an enzyme that
splices out genes flanked by LoxP sites only in the regions where
Cre is expressed, thereby achieving tissue-specific gene deletion
whenCre-expressingmice are crossed withmice containing LoxP
sites around the gene of interest (see (Kos, 2004) for full review
of Cre-LoxP mice). The ability to regulate Cre expression with
diverse tissue-specific promoters provided better tissue selectivity
of the knockout, but temporal control was still tied to the
promoter driving Cre expression.
Later modifications to Cre-LoxP system had led to an
inducible form of Cre that substantially improved temporal
specificity in transgenic mice. Specifically, the activity of Cre was
engineered to depend on either the introduction of a synthetic
hormone or the doxycycline system, whereby Cre activity and
the resulting genetic knockout occur only after the activating
compound is delivered (Guo et al., 2005; Feil et al., 2009).
Inducible Cre systems provide experimental control over the
onset of gene deletion (to within days or weeks following delivery
of the activating compound), and at the same time ensuring
normal gene function during development (Michel et al., 1979;
Guo et al., 2005; Feil et al., 2009; Wilson et al., 2014). In addition
to these types of transgenic strategies, wherein Cre is provided by
a transgenic mouse, various viral methods have been developed
to exogenously provide Cre activity by microinjection of a viral
vector. When administered to transgenic mice with LoxP sites
flanking the gene of interest, this method further extended the
temporal and spatial specificities of the knockout, although it
requires the additional step of viral production and stereotaxic
surgery for targeted viral delivery (Sinnayah et al., 2004). One
disadvantage of these systems, however, is the necessity to
develop and maintain transgenic mouse lines expressing floxed
genes of interest and the difficulty in targeting multiple genes
simultaneously.
In parallel with advancements in transgenic mice, various
RNA interference (RNAi) techniques were developed to
decrease gene expression in wild-type rodents without requiring
maintenance of large transgenic mouse colonies. RNAi makes
use of an endogenous pathway within most eukaryotic cells,
whereby double-stranded RNA is processed by the enzyme Dicer
and loaded into a RISC (RNA-induced silencing complex), which
recognizes RNA transcripts that share homology with the RNA
loaded into the RISC (Wilson and Doudna, 2013). Although
the experimentally determined RNA introduced to this system
can take many forms, shRNA is most commonly utilized in
neuroscience. In this system, shRNA designed to target a specific
transcript is overexpressed in particular brain regions through
the use of viral vectors, mostly commonly adeno-associated viral
vectors. An advantage of this approach is that it can be performed
in wild-type rodents and the degree of gene knockdown can be
experimentally controlled. In addition to target-specific brain
regions, specific cell types may also be targeted through the use
of different AAV serotypes (Choi et al., 2005) or different types
of viruses, such as herpes simplex virus (HSV; Burton et al.,
2002). Although designing the shRNA may be less time and
labor intensive than creating new lines of transgenic mice, the
procedure is not trivial. Typically, many different shRNAs are
individually designed and validated before sufficient knockdown
is obtained (Choi et al., 2005). A primary disadvantage of this
approach is the potential for off-target effects, which hampers
the interpretation of results obtained from shRNA studies
(Birmingham et al., 2006; Jackson and Linsley, 2010; Moore et al.,
2010).
Each new tool we discussed exhibits improvement over
previously available methods, but extensive design and time
requirements of each strategy limit flexible switching to new
gene targets. Here, we discuss the next generation of genetic
tools, focusing first on recent advancements in the highly flexible
CRISPR/Cas9 system, which enables simple “plug and play”
mechanics to studymany different genes simultaneously. Second,
we focus on removing the need for viruses/mouse models by
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highlighting the advances made in anti-sense nucleotides, mainly
anti-sense oligonucleotides (ASOs) and Morpholinos, which can
be directly added to the brain without any delivery system, to
effect gene regulation.
USING CRISPR/Cas9 FOR GENE
MODULATION IN THE BRAIN
The discovery of the CRISPR/Cas9 system and its adaption
for use in gene editing has sparked a revolution in many
scientific fields due to its ability to edit specific sequences in
the genome. Initially, this may seem no more advantageous
then various RNAi methods already in use. However, the
true power of the CRISPR/Cas9 system lies in is its simplicity
and flexibility. Whereas RNAi development can be time
consuming and/or costly, often requiring many iterations
before producing an acceptable level of knockdown (Moore
et al., 2010), nearly every targeting sequence designed for
use with CRISPR/Cas9 has a high chance of producing the
desired knockout (Cong et al., 2013; Mali et al., 2013). This
efficiency allows for rapid and effective switching between
gene targets and importantly, for developing multiple
targeting sequences to edit multiple genes simultaneously.
In addition, CRISPR/Cas9 tools can be easily developed in
individual laboratories with minimal need for specialized
knowledge. Finally, the CRISPR/Cas9 system is very user-
friendly, with fully-accessible resources for generating targeting
constructs available at no cost (See http://www.genome-
engineering.org for in-depth CRISPR/Cas9 protocols and
resources).
CRISPR/Cas9 is a system in which an RNA-guided
riboprotein, Cas9, cleaves DNA at genomic sites that are specified
by a target sequence encoded within CRISPR. The system was
discovered as a bacterial/archaea immune response, which
defends the organism against viral infections by incorporating
short segments of invading DNA within specialized regions
of the genome called CRISPR (clustered regularly interspaced
short palindromic repeats). The short fragments of foreign DNA
contained within CRISPR act as a guide that targets invading
DNA through association with Cas9 (CRISPR-associated protein
9), a nuclease that uses the guide sequence to detect and cut any
DNA that matches the foreign fragment encoded in the CRISPR
array. By co-opting and engineering this system, scientists are
able to dictate which fragments are “foreign,” or rather which
genes/fragments will be targeted for experimental purposes
(Cong et al., 2013; Mali et al., 2013). This system allows for
the introduction of double-stranded DNA breaks (dsDNA)
at nearly any specified sequence within the genome (for an
in-depth look at the Cas9 system, see review, Hsu et al., 2014).
Once introduced, double stranded DNA breaks can be utilized
to create gene knockouts or knock-ins at the location of the
double-stranded DNA break, as described below.
Using CRISPR/Cas9 for Gene Knockout
The process of knocking out a gene using CRISPR/Cas9 is both
straight-forward and fast. First, an analog of the CRISPR guide
region found in bacterial systems must be created to identify the
gene region that is to be targeted. This is achieved by creating
a single guide RNA (sgRNA), which is used to direct Cas9 to
the gene of interest, where it causes a dsDNA break. In order
for this to occur, the region to be cut must also contain a
PAM (protospacer adjacent motif), a simple nucleotide sequence
consisting of any base followed by two Gs. Once a cut-site is
created, it initiates dsDNA break repair by the non-homologous
end joining (NHEJ) pathway in the brain, which frequently
results in insertion/deletion mutations (INDELs; Heidenreich
et al., 2003). In cases where INDELS do not form immediately,
Cas9/sgRNA will rebind that location and cut again, increasing
the likelihood of successful INDEL formation. Introducing
INDELS particularly to the coding regions of target genes causes
frameshift mutations that form the basis of CRISPR/Cas9-based
gene knockout (Streisinger et al., 1966). This system has several
advantages over previous approaches, including the overall ease
of use, with no specialized techniques required to create and
validate the setup by end-user labs. For example, a laboratory
needs only to know basic molecular cloning and cell culture
techniques to create and validate the sgRNA.
In addition to the relative ease of developing CRISPR/Cas9
to achieve highly efficient gene editing, this system can be easily
adapted to target multiple genes simply by creating additional
sgRNA sequences directed against different gene targets (Shalem
et al., 2014). This may be important for studying the effects
of several gene products or pathways in behavior, or for
deleting proteins that are encoded by multiple genes. Similarly,
gene targets can be switched if additional regulatory genes are
identified, with minimal effort. The use of Cas9 to induce gene
deletions in the brain is less common than its use in other cell
types. However, studies have shown that CRISPR/Cas9 can be
used to delete genes in the brain (for example, Mecp2; Swiech
et al., 2015). In this example, knockout was achieved through
the use of two AAVs, one to express Cas9 and one to express
the sgRNA and GFP. These viruses were mixed and injected into
the hippocampus where they resulted in ∼80% co-transduction
rate and up to a 70% reduction in Mecp2-positive cells in the
dentate gyrus. When memory was assayed using contextual fear
conditioning, Mecp2-mutated mice showed reduced freezing
behavior, indicating poor memory and thus illustrating the utility
of the Crispr/Cas9 approach in mice behavioral studies.
Swiech et al. (2015) further demonstrated the power
of CRISPR/Cas9 for exploring functional outcomes of
multiple genes with overlapping functions. Specifically, the
authors developed three sgRNAs targeted against key DNA
methyltransferase enzymes, Dnmt1, Dnmt3a, and Dnmt3b.
They targeted each with a sgRNA and showed simultaneous
co-knockouts of each one (% reduction in Dmnt+ cells: 60,
42, and 17% for Dnmt1, 3a, and 3b, respectively). This study
provided the first evidence of simultaneous multi-gene knockout
in the brain with only the addition of multiple sgRNAs to
the system, demonstrating the feasibility of this approach in
neuroscience. Consistent with previous studies using classical
knockout approaches (Feng et al., 2010), Swiech et al. found
no behavioral effects when each gene was knocked down alone.
However, when multiple genes were knocked out simultaneously
using the multiplexed CRISPR/Cas9, mice showed poor memory.
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Observing a memory phenotype only with simultaneous
knockdown of multiple DNMTs demonstrates the functional
significance of this system and the potential for multi-gene
targeting with CRISPR/Cas9 in the brain. However, this study
also reveals a marked decrease in knockdown efficiency with
an increased number of sgRNAs. Specifically, the knockdown
efficiency was reduced from 70% when only one gene was
targeted (MecP2) to 60, 42, and 17% when three DNMTs
were targeted simultaneously. It is unclear whether this loss
in efficiency is indicative of typical outcomes of multiple gene
deletions in the brain, or if this effect is locus specific, as local
chromatin configuration may influence the efficiency of the
sgRNA–Cas9 complex (Wu et al., 2014a). In vitro, thousands of
sgRNA–Cas9 complexes have been multiplexed to enable high-
throughput screening (Shalem et al., 2014, 2015; Zhou et al.,
2014), demonstrating the capacity of the system to handle many
targets. Furthermore, multi-target studies in the brain are needed
to better characterize the efficacy of multi-gene knockdown, but
the potential of CRISPR/Cas9 to knockout genes of interest in
neuroscience remains vast.
Use of Cas9 for Knock-in Mutations
As briefly mentioned above, CRISPR/Cas9 is a flexible
and versatile system with the potential for multiple gene
editing functions, including the introduction of knock-in
mutations. Knock-in mutations may be of particular interest
for understanding disease states in which particular mutations
have been identified. As with gene knockout, dsDNA breaks
caused by Cas9 can also be harnessed to produce knock-in
mutations, typically through the homology-dependent repair
(HDR) pathway (Ran et al., 2013a). This pathway is a normal
DNA repair pathway that repairs dsDNA breaks by comparing
the region containing a dsDNA break with a nearby homologous
region, typically a sister chromatid, and repairs the dsDNA break
using the homologous region as a template. This process can be
co-opted to achieve high knock-in levels in regions targeted by
sgRNA by introducing an engineered DNA sequence flanked by
homologous regions that serve as repair templates (Ran et al.,
2013a).
The main limitation of this mechanism for neuroscience
applications is its reliance on HDR, which is not usually present
in terminally differentiated cell types like neurons (Ran et al.,
2013a). For this reason, efforts to produce targeted knock-ins
using HDR-based tools in neurons have yet to be successful.
However, HDR-based knock-ins have successfully introduced
gene mutations in vivo in the lungs, resulting in nearly equal
frequency of knock-in mutations when compared to INDEL-
based knockouts (Platt et al., 2014). Nonetheless, if efforts
to transition HDR-based mutations to neurons fail, efforts to
harness the NHEJ pathway, which is found in the brain, show
some promise for producing knock-in mutations (Maresca et al.,
2013; Auer et al., 2014), although this approach has not yet been
demonstrated in neurons. Interestingly, Cpf1, an enzyme similar
to Cas9, is a newly characterized member of the Cas family.
Similar to Cas9, Cpf1 causes double-stranded DNA breaks, but
unlike Cas9, the DNA break results in overhanging “sticky
ends” that promote NHEJ-based knock-ins (Maresca et al., 2013;
Zetsche et al., 2015). These advancements suggest that Cpf1
may be a solution for obtaining efficient knock-in mutations
in the nervous system (Platt et al., 2014). This approach has
many potential applications that would allow various forms
of mutations, including disease-specific mutations found in
humans, as well as loxP sites for gene deletion, to be introduced
directly into the nervous system. The feasibility and utility of such
applications will depend on their validation at sufficiently high
efficiency to make them useful for in vivo work.
While CRISPR/Cas9 has most commonly been used for direct
gene editing, this system may also be used to modulate gene
expression without editing the genome directly. Two primary
methods have been developed for indirect regulation of gene
activity, each relying on a mutated form of Cas9 that lacks
nuclease activity (dCas9; Cheng et al., 2013; Gilbert et al., 2013;
Maeder et al., 2013). The two methods vary in the components
modified, with one modifying the dCas9 and the other modifying
the sgRNA (Cheng et al., 2013; Gilbert et al., 2013; Maeder et al.,
2013; Konermann et al., 2015). Irrespective of the target, both
modifications operate on the same basic premise: instead of using
sgRNA–Cas9 to cut DNA, the sgRNA–Cas9 is used as a scaffold
for other modifying enzymes to be recruited to the targeted locus
to modify its function.
Using sgRNA/Cas9 as a Scaffold to Inhibit
or Activate Genes
sgRNAs can target almost any site within the genome with
excellent selectivity, suggesting that sgRNA–dCas9 complexes
can also be targeted to specific regulatory positions of a given
gene. Indeed, recent studies demonstrated either promoter- or
enhancer-selective targeting of sgRNA–dCas9, which was used as
a scaffold for recruiting transcriptional activators or repressors
to the designated target region, thereby modifying the gene’s
transcriptional activity (Shalem et al., 2015). This scaffolding
function can be achieved with multiple approaches either by
fusing the transcriptional modulator directly to dCas9 (Cheng
et al., 2013; Gilbert et al., 2013; Maeder et al., 2013; Perez-
Pinera et al., 2013) or by fusing a repeated motif to dCas9 to
attract multiple copies of the endogenous modulator to a locus
(Tanenbaum et al., 2014). Here, we will focus our attentions on
a third option, in which the sgRNA itself is modified to act as a
scaffold. This latter option represents themost flexible and robust
method of recruiting particular factors to the gene of interest with
CRISPR/Cas9.
Many types of proteins have evolved to bind specific RNA
sequences, including MS2 coat protein (MCP). MCP binds
to RNA through an MS2 stem loop formed by a specific
RNA sequence. Such stem loop structures can be engineered
into endogenous loops in tracrRNA, a component of sgRNA
that recruits Cas9. These stem loops are recognized by viral
coat proteins, such as MCP, which can be engineered to
fuse with transcriptional activators or repressors. Fusing the
transcriptional activator HSF1 to MCP has been used to achieve
robust (>100x) activation of target genes (Figure 1). Similarly,
pairing this complex with transcriptional repressors results in
robust inhibition (>80%; Gilbert et al., 2014; Konermann et al.,
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FIGURE 1 | The use of CRISPR/Cas9 for simplexed and multiplexed
gene modulation. (A) CRISPR/Cas9-based gene knockouts have been
demonstrated in the brain in both simplexed (1 target) and multiplexed (≥2
genes) fashions. Although our example demonstrates three gene targets,
additional targets may be added. In each case, knockdown is achieved by
creating a single guide RNA (sgRNA) specific to the gene of interest, which
recruits Cas9 to cut the DNA in order to induce frameshift mutations that
knock out the gene. Frameshift mutations are illustrated as red marks on the
DNA. The use of multiple sgRNAs can induce knockouts of multiple genes
simultaneously. (B) An inactive form of Cas9, known as dCas9, can be used to
modulate gene expression by recruiting transcriptional regulators to
genes of interest, but this system has yet to be demonstrated in the brain. In this
(Continued)
FIGURE 1 | Continued
system, the sgRNA–dCas9 molecule is treated as a scaffold for recruiting
other proteins, most commonly transcriptional activators (blue squares) or
transcriptional repressors (red circles) to the specified location within the
genome. This is not limited to transcriptional regulators and can easily be
modified to bring epigenetic-modifying enzymes or specific transcription
factors to these locations. This is accomplished by modifying the sgRNA to
include MS2 sequences (green half circle), which is recognized by the MS2
coat protein, MCP (green >). The MS2 coat protein is fused to the protein of
interest, in this case either a transcriptional activator or repressor. The
MS2-fusion protein is transduced into the cells of interest in addition to the
dCas9 and the modified sgRNA, directing the activator/repressor to the
specific loci. It is important to note that with only an MS2-fusion construct,
only 1 type of fused protein can be delivered. That is, either transcriptional
activation or repression can occur, but not both. Simultaneous multiplexing of
repressors and activators to distinct loci is demonstrated in (C), where
additional stem loops (the PP7 stem loop, purple ) and stem loop binding
proteins (PP7 binding protein, purple ) are added to the system and fused to
specific DNA-modifying enzymes. This allows separate proteins to be recruited
to distinct loci, achieving mixed activation/repression of different genes.
2015), demonstrating a high degree of efficacy for modifying gene
function.
One advantage of engineered sgRNAs is the potential to
multiplex distinct and multiple gene loci to repressors or
activators simultaneously, such that some genes are turned off in
the same model in which other genes are turned on. By relying
on different stem loops that are recognized by different proteins
[PP7 stem loop, PP7 coat protein; PCP Lim and Peabody, 2002;
Shalem et al., 2015; Zalatan et al., 2015], one can ensure that
certain sgRNAs activate their loci by pairing them with MS2
loops, while engineering other sgRNAs to repress their loci by
pairing them with PP7 loops (Zalatan et al., 2015). Activation
and overexpression of distinct gene products are achieved
by simultaneously expressing MCP fused to a transcriptional
activator and PCP fused to a transcriptional repressor. A major
advantage of this approach is the ability to induce opposing
regulatory effects on different genes, a strategy that can be easily
scaled up to include any number of loci because of the small size
of sgRNAs (Zalatan et al., 2015). The ability to active and silence
different genes is important in investigating the neural basis of
behavior.
One novel application of the scaffolding approach is the
ability to create position-specific epigenetic modifications at
behaviorally relevant genes. Broader accessibility of genome-
wide sequencing approaches has redefined our understanding of
epigenetic modifications, highlighting the crucial role of gene-
and region-specific effects of epigenetic modifications on gene
activity (Bargaje et al., 2012; Shlyueva et al., 2014; Zovkic et al.,
2014). Until recently, the study of epigenetics relied almost
exclusively on pharmacological tools that resulted in global
effects across all genes in the brain region of interest. However,
recent work using dCas9 as a scaffold showed a high capacity
to regulate epigenetic changes at particular genes, as well as
particular regulatory regions of the gene. Specifically, in the
first study demonstrating the feasibility of this approach, the
core domain of the p300 histone acetyltransferase enzyme was
fused to dCas9 and targeted to either promoter or enhancer
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regions of genes by using region-specific sgRNAs (Hilton et al.,
2015). This resulted in site-specific changes in histone acetylation
and transcription (Hilton et al., 2015), providing the first direct
evidence that selective changes in histone acetylation at gene
promoters support gene activity. This innovation expands the
toolbox available for studying the complex interaction between
genes, epigenomics, and behavior.
While Cas9-based gene editing has been successfully
demonstrated in vivo in the nervous system (Platt et al., 2014;
Swiech et al., 2015), the use of CRISPRi (using dCas9 to repress
loci) or CRISPRa (using dCas9 to activate loci) has not been
demonstrated in the brain. However, there is no reason that
these methods will not translate into the CNS, since the main
requirement for the system to work is for Cas9/sgRNA to bind
to a gene locus, which has already been demonstrated to occur
in the brain with wild-type Cas9 (Platt et al., 2014; Swiech et al.,
2015). In addition, these methods can even be combined with
light-activation domains, giving greater temporal specificity to
the transcriptional manipulations (Wu et al., 2010; Konermann
et al., 2013; Nihongaki et al., 2015; Polstein and Gersbach, 2015).
The major limitation to these methods is the need for additional
constructs, such as the MCP-binding protein fused to the desired
enzyme and either additional AAVs or viruses with large packing
limits, such as herpes simplex virus (HSV). The use of viruses
to deliver CRISPR/Cas9 in the brain is discussed further in the
sections given below.
OFF-TARGET EFFECTS OF CRISPR/Cas9
Although CRISPR/Cas9 primarily targets specific loci within the
genome, some off-target activities have been reported at sites
homologous to the sgRNA sequence (see Wu et al., 2014b for an
in-depth review). The frequency of off-target binding depends on
the guide sequence, with some sgRNAs having as few as 10 off-
target sites in the genome, and others having many more (Kuscu
et al., 2014; Frock et al., 2015). If off-target effects are of particular
concern, then they can be handled in a number of ways. First,
the guides themselves can be optimized to reduce the number of
homologous targets in the genome. Off-target effects can occur
because the Cas9–sgRNA complex can tolerate between 3 and
5 mismatches in the guide, while still retaining some functional
capacity at off-target sites (Fu et al., 2014). Therefore, designing
sgRNAs that minimize homology to other sites is the simplest
strategy for reducing off-target effects. Other approaches include
decreasing the size of the sgRNA from the traditional 20 to 17–
19 bp, which can reduce or eliminate off-target activity without
negatively affecting the activity at the target site (Fu et al., 2014).
Modifications can also be done to Cas9, as evidenced by eCas9,
a mutated form of Cas9 that exhibits vastly decreased off-target
activity compared to wild-type Cas9 (Slaymaker et al., 2016).
Perhaps the best way to overcome potential off-target effects is to
simply verify any observed results with two separate sgRNAs for
the same gene, ensuring that the genes do not have homologous
sgRNAs. Alternatively, appropriate targeting can be confirmed
by rescuing the deletion phenotype by re-introducing the deleted
gene with overexpression approaches.
Other strategies for reducing off-target effects include using
a system in which two sgRNAs must bind the same region to
achieve full nuclease activity, using either paired nickases (Ran
et al., 2013b) or FokI (Guilinger et al., 2014; Tsai et al., 2014;
Wyvekens et al., 2015). The paired nickase approach is based
on the observation that two separate sites within Cas9 cut each
strand of DNA to achieve the DSBs needed for gene deletion.
Mutating one of these sites to prevent cleavage ensures that
one sgRNA/“nickase” pair can nick the DNA only on a single
strand, thus precluding INDEL formation. However, when two
nickases directed against opposite strands of DNA occur in close
proximity, DSBs can be induced and gene deletion can occur.
This added requirement for two sgRNAs within the same target
region effectively reduces off-target activity. The Fok1 method
follows the same principle, but instead of using a nickase, Cas9
is mutated to prevent any nuclease activity (dCas9). The dCas9
is then fused to a Fok1 monomer to produce fCas9. Fok1
has no nuclease activity as a monomer, but it readily cleaves
DNA upon dimerization. Therefore, by designing two sgRNAs
approximately 20bp apart, both fCas9s will bind within the same
region, allowing Fok1 to dimerize and induce a DSB. Although
these approaches greatly reduce off-target activity, they require
the design of additional vectors and may require more viruses
to deliver modified Cas9s and additional sgRNA, making it
cumbersome for in vivo use in the brain.
DELIVERING CRISPR–Cas9 INTO THE
BRAIN
Although there are many advantages of CRISPR/Cas9 as a gene
editing tool in the brain, the application of this technology in
neuroscience has been slow. One reason for this may be the
difficulty of delivering Cas9 into the brain. Cas9 is a large protein,
with the promoter and coding sequence spanning more than 4 kb
in size, which itself can fill the packaging limit of AAVs. When
combined with sgRNAs and the fluorophores required to track its
expression, the experiment can easily exceed the packaging limit
of AAV vectors, which typically ranges from 4 to 5 kb (Wu et al.,
2010). Nevertheless, multiple strategies have been developed to
overcome this barrier, and we will discuss three of the most viable
solutions here.
One simple solution is offered by the development of a
Cas9 transgenic mouse that has Cas9 (or a Cre-mediated
Cas9) knocked into the ROSA26 locus (Platt et al., 2014),
which is commonly used to drive robust and tissue-wide gene
expression (Casola, 2010). The Cas9 mouse eliminates the
issue of Cas9 packaging and allows viral vectors to be used
exclusively to produce sgRNA or multiple sgRNAs, as well as any
other experimentally required proteins. This method has been
successfully utilized to knockout genes in the brain and even
to drive knock-in mutations in the lungs (Platt et al., 2014).
Unfortunately, this method precludes the use of tool kits based
on dCas9, including CRISPRi or CRISPRa, which would require
the creation of an additional dCas9 transgenic line. Another
limitation of this solution is the need to maintain a dedicated
mouse line, which eliminates one of the primary advantages of
Frontiers in Genetics | www.frontiersin.org 6 January 2016 | Volume 6 | Article 362
Walters et al. Advanced In vivo Gene Editing in the Brain
using Cas9 over other Cre/LoxP lines. In addition, the need for a
dedicated mouse line precludes the flexibility of moving research
questions out of mice into other model organisms.
An alternative solution to the size problem involves the use of
multiple AAVs, in which oneAAVdelivers Cas9, whereas another
AAV delivers the sgRNA and any other required proteins. This
method has been used to drive knockout mutations within
the brain and even to multiplex the knockout of three genes
simultaneously (Swiech et al., 2015). This method is effective
(some labs report 70–80% co-transduction rate) and as such, it
may provide a solution for using CRISPRi or CRISPRa in vivo,
particularly if larger packaging size viruses, such as HSVs, are
used.
Finally, homologs of Cas9 exhibit a natural variation in size.
Cas9 derived from Streptococcus aureus is significantly smaller
than the Cas9 from Streptococcus pyogenes, the Cas9 discussed
thus far. The smaller Cas9 allows the Cas9, sgRNA, and GFP to
be packaged together in one AAV (Ran et al., 2015). Together,
these solutions and ongoing innovations make CRISPR/Cas9
increasingly accessible for in vivo use with various applications
in neuroscience.
Although many of the advanced uses of the CRISPR/Cas9
system have not been attempted in vivo, the system as a whole
is poised to revolutionize gene editing within the brain. With
the growth of neuroepigenetics as a field, the use of Cas9 in
modulating epigenetic changes in a locus-specific way is ready
to take center stage both in neuroscience and in biology in
general. With the currently available technologies, neuroscience
laboratories can easily start examining single and multi-gene
knockouts specifically within the brain. Although the CRISPRi,
CRISPRa, and epigenetic modulator methods have not yet been
attempted in the nervous system, they are ready for in vivo brain
validations.
DISRUPTING GENE EXPRESSION IN THE
BRAIN WITHOUT THE NEED FOR VIRUSES
OR MOUSE MODELS
Most modern techniques for modulating gene expression in the
brain require the use of an engineered viral vector or mouse
model to introduce the gene disruption. Several alternative
strategies have been developed to obtain rapid knockdown
without the use of viruses, including the use of anti-sense
nucleotides, which can be readily purchased for in vivo
applications, bypassing the need to employ a viral vector or
transgenic mice to achieve gene knockdown.
Use of Anti-sense Nucleotides for Gene
Disruption in the Brain
Anti-sense nucleotides are a widely used method for gene
interference. This method relies on relatively short (8–50 bp)
oligonucleotides that are complimentary to the sense strand
of mRNA. This approach varies from RNAi in that the
oligonucleotides are typically composed of DNA rather than
RNA, are single stranded, and do not require Dicer processing or
incorporation into a RISC (see above). Depending on the targeted
location within the transcript, anti-sense mRNA inhibition can
be used to induce transcript degradation, inhibit translation,
cause aberrant splicing, or interfere withmiRNAmaturation. The
primary goal of thesemethods is to achieve an inhibition of genes,
with the exception of aberrant splicing, whichmay also be utilized
to produce alternative splicing patterns in some transcripts
(Passini et al., 2011; Porensky et al., 2012). In most instances,
transcript degradation is mediated primarily by recruiting RNase
H to degrade DNA–RNA hybrids formed by the binding of anti-
sense DNA to its target mRNA (Wheeler et al., 2012), resulting in
rapid degradation of the target transcript.
Importantly, the structure of the anti-sense DNA allows
these oligonucleotides to be readily taken up by cells in a
process called gymnosis, thus eliminating the need for viral
vectors, transfection agents, or transgenic mice. However,
widespread use of this approach in vivo is limited by extensive
susceptibility of the oligonucleotides to degradation, marked
by the near-ubiquitous presence of nucleases that break their
phosphodiester bonds, thereby causing rapid degradation of
the anti-sense oligonucleotides (Wickstrom, 1986; Akhtar et al.,
1991) and lack of cell specificity. For this reason, research
has focused on developing potential modifications that may
stabilize oligonucleotides in vivo by reducing their susceptibility
to degradation, with efforts resulting in two different classes of
anti-sense nucleotides. The first major category consists of anti-
sense oligonucleotides (ASO) that use various modifications to
the existing sugar backbone to prevent degradation, whereas
morpholinos represent an additional category that utilizes an
entirely different type of backbone to achieve the same goal.
Both techniques prevent the molecule from being degraded
by traditional nucleases and have progressed to the point of
achieving efficient gene inhibition in vivo without the need for
viral vectors. We discuss each of these categories and their
modifications below.
Using ASOs for Direct Disruption of Gene
Expression
ASOs initiate degradation by binding to target RNA to form
DNA–RNA hybrids, which recruit RNase H to degrade the
RNA portion of the hybrid (Smith et al., 2006). As mentioned
previously, stable knockdown is achieved through several distinct
modifications of the sugar backbone or of phosphodiester bonds,
with stability and efficacy of the ASO affected by the specific
type of modification (see Figure 2). Initial modifications altered
the phosphodiester bond to a phosphorothioate bond, thus
increasing the half-life of the ASO in serum from 1 to over 9 h
[9 h in human serum and up to 19 h in rat CSF (Campbell et al.,
1990)]. However, this modification also weakened the bonding
affinity of the ASO to its target mRNA, thus necessitating higher
doses of ASO and resulting in increased cytotoxicity and off-
target effects (Levin, 1999). In this first generation of modified
ASOs, the phosphorothioate backbone was still recognized as
DNA by RNase H, thus retaining the capacity to cleave the
RNA portion of the DNA–RNA hybrid (Wu et al., 2004;
Bennett and Swayze, 2010). In addition, this modification also
maintains the negative charge of the ASO, allowing it to cross
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FIGURE 2 | Modifications of anti-sense nucleotides. Anti-sense nucleotides are delineated into two major types, anti-sense oligonucleotides (ASOs), which
maintain a ribose/deoxyribose backbone, and Morpholinos, which replace the sugar backbone with a morpholine group. ASOs have been modified in several ways to
increase their resistance to endogenous nucleases, either by changing the phosphodiester bond or adding molecules onto the sugar backbone itself. Initial
modifications altered the phosphodiester bond to a phosphorothioate bond by replacing an O− with an S−, resulting in robust nuclease resistance. However, a
disadvantage of this modification is the reduced affinity for target mRNA, which has been addressed by combining phosophothioate with modifications to the 2′ C that
replace the H with an O-alkyl group, either an O-methyl or O-methyoxy-ethyl (MOE) or an LNA configuration. These modifications further enhance nuclease resistance
and increase the affinity of the ASO for mRNA. However, all of these modifications require the addition of oxygen (colored in green) to the 2′ C in the deoxyribose base,
thus changing the sugar from deoxyribose into ribose and preventing the recruitment of RNase H to degrade transcripts. Further, modifications designed to recruit
RNase H have been achieved by forming “gapmers” that consist of RNA with “gaps” filled by DNA, allowing for successful recruitment of RNase H. Morpholinos
reduce nuclease degradation by completely replacing the sugar backbone with a morpholine group. Morpholinos are unable to recruit RNase H, and importantly, they
cannot cross the cell membrane without the addition of an octaguanidine dendrimer (vivo-Morpholino). The traits of each modification are summed up in the bottom of
the panel.
the plasma membrane and be taken up by the cell in its native
form.
Successful application of ASOs modified by phosophothioate
bonds was reported for both chronic and acute treatment
protocols in the brain (Jan et al., 2015), each achieving
moderate levels of target knockdown. However, the higher
dose and time required for phosphorothioate ASOs to produce
efficient knockdown has been associated with neural tissue
damage (Engelhard, 1998; Engelhard et al., 1998), thereby
limiting their utility. Alternative backbone modifications, such as
phosphoramidate bonds, have also been investigated, but their
in vivo effectiveness in the brain is only a beginning to be
investigated (Crooke, 2008). Continuing efforts to develop new
modifications, which retain high levels of RNA-binding capacity
while achieving high levels of stability, will be a key to more
wide-spread use of this technology in neuroscience.
To this end, some success has been reported with other
modifications to the ASO sugar ring that increase potency and
protect from degradation. One successful approach utilizes a
ribose instead of deoxyribose for the sugar moiety, which is
then further modified at the 2′ hydroxyl group by adding either
a methyl, or the more modern methoxy-ethyl (denoted MOE)
group to the 2′ oxygen. These modifications result in improved
binding affinity of the ASO, while also protecting it from
degradation. However, the conversion of deoxyribose into ribose
transforms the oligo into an RNA oligomer, thus precluding the
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recruitment of RNase H as a mediator of transcript degradation
(Baker et al., 1997). That is, RNase H activity is activated in
the context of DNA/RNA duplexes, such that conversion of the
ASO to RNA produces RNA/RNA duplexes that do not recruit
RNaseH (Monia et al., 1993). Although this precludes direct
modulation of mRNA degradation, these ASOs can still cause
translational inhibition through additional pathways, including
selective targeting of the transcript near the translational start
site, which results in gene inhibition through steric hindrance
of protein translation (Charlier et al., 2005; Osman et al., 2012;
Pao et al., 2014). Gene silencing can also be achieved by exon
skipping that targets ASOs to specific junctions in the pre-mRNA
(Disterer and Khoo, 2012; van Roon-Mom and Aartsma-Rus,
2012), resulting in the production of functionally inert proteins,
or steric hindrance of translation (van Roon-Mom and Aartsma-
Rus, 2012). An advantage of exon skipping as a knockdown
strategy is that it often results in partial knockdown that is
relatively amenable to titration (Disterer and Khoo, 2012; van
Roon-Mom and Aartsma-Rus, 2012). This strategy is particularly
useful for studying many outcome measures in neuroscience that
are typically affected by varying levels of gene expression rather
than the complete presence or absence of particular proteins.
Alternatively, exon skipping can be utilized to restore
function of a previously dysfunctional gene by reinstating a
disrupted reading frame, a strategy that is particularly useful for
therapeutic intervention in several disease states (Chamberlain
and Chamberlain, 2010; van Roon-Mom and Aartsma-Rus,
2012). For example, MOE-modified ASOs have been successfully
used in the brain to treat spinal muscular atrophy (SMA), which
is caused by null mutations in the Smn1 gene (Passini et al.,
2011). Gene editing efforts are based on the observation that the
Smn1 gene has been duplicated to produce a mostly inactive gene
called Smn2, which is typically silent due to a splice mutation
that prevents the inclusion of exon 7 (Sun et al., 2005). Passini
et al. (2011) tested the capacity of MOE-modified ASOs to
restore function to the silent Smn2 gene by targeting the silencing
splice mutation in Smn1 mutant mice. Using intra-ventricular
injections of the ASO, the authors found that Smn2 silencing
was reversed through the inclusion of exon 7 into the Smn2
transcripts, thereby ameliorating SMA pathology (Rigo et al.,
2014). Although ASOs are primarily capable of knocking down
gene expression, these data demonstrate that ASOs do have a
limited capacity to enhance gene activity but only in the context
of repairing expression deficits associated with endogenous exon
skipping.
Using Locked Nucleotides for Gene
Knockdown
A final ASO modification, which has been through several
iterations since its introduction, incorporates locked nucleotides
(LNA) into the ASO to further increase the binding affinity and
knockdown efficiency. LNAs differ from normal nucleotides in
that the ribose backbone has been changed to “lock” it into
C3′ endo position, thus locking it into a formation that favors
normal base pairing (Kurreck et al., 2002). This locking is
achieved by connecting the 2′ hydroxyl group, which causes the
nucleotide to be recognized as RNA, to the 4′ carbon group to
create a stable structure that drastically enhances the binding
affinity of the bases and decreases its susceptibility to degradation
(Frieden et al., 2003). An important advantage of LNA-based
oligos is their retained capacity to cross the blood–brain barrier
endogenously, making their delivery into the brain possible. In
addition, these oligos may have the most robust defense against
degradation and the highest binding affinity among various
oligos we have discussed (Wahlestedt et al., 2000; Braasch et al.,
2002). However, these modifications still have several major
limitations. As discussed in earlier sections, the conversion of
oligos to RNA precludes the recruitment of RNase H and requires
the use of alternative pathways to achieve gene knockdown.
Moreover, LNA-based oligos appear to suffer severe toxicological
problems (Kurreck et al., 2002; Swayze et al., 2007; Kakiuchi-
Kiyota et al., 2014) and off-target effects (Mook et al., 2010), thus
limiting their usefulness in vivo.
Much of the current effort is focused on retaining the various
2′ hydroxyl modifications for their capacity to protect oligos
from degradation, while also gaining the ability of DNA-based
oligos to recruit RNase H when they form a complex with target
mRNA. Successful efforts in this search have resulted in a new
generation of ASOs that are referred to as “gapmers,” which
retain their 2′ hydroxyl groups, but only incorporate them into
the first and last five bases of the ASO, thus creating a “gap”
of unmodified DNA in the intervening 10 bases (Jepsen and
Wengel, 2004; Jepsen et al., 2004; Smith et al., 2006). The hybrid
gapmer allows the ASO to benefit from the increased half-life and
improved affinity associated with these modifications. However,
as the internal 10 bases are DNA, the ASO–mRNA complex is
recognized as a DNA–RNA hybrid and degraded by RNase H,
thus creating a stable structure that retains RNase H activity.
Various iterations of this system exist that are dependent on three
main modifications of the 2′ hydroxyl group that increase its
stability and binding capacity, as already discussed. The main
modifications used in gapmer context include LNAs or the
addition of either methyl or MOE groups (Kordasiewicz et al.,
2012; Stanek et al., 2013; Mutso et al., 2015).
Gapmers have been successfully used in several in vivo
applications, including the knockdown of the mutant
Huntington’s gene (Htt) in mouse models of Huntington’s
disease (Carroll et al., 2011), demonstrating their utility
in vivo. Specifically, the authors made 2′MOE gapmers with
a phosphorothioate backbone and locally injected it into the
striatum (Carroll et al., 2011). Two weeks after a single ASO
injection, mutant Htt protein levels were reduced by 60%
and disease progression was delayed (Carroll et al., 2011;
Kordasiewicz et al., 2012). Others researchers have found
long-lasting decreases in another disease-related gene, Sod1, with
minimal off-target effects after 28 days of ASO administration
directly into the brain (Smith et al., 2006), suggesting their
potential utility for achieving stable knockdown in vivo.
Overall, LNA-based gapmers have received much attention
because of their robust binding affinity. In vivo, these gapmers
demonstrate impressive results with some ASOs achieving 90%
reductions in target transcripts at picomolar concentrations
(Dias and Stein, 2002). Unfortunately, the dose required for the
majority of ASOs in vivo can result in severe toxic side effects
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(Swayze et al., 2007; Seth et al., 2009), requiring tremendous
caution to be used if applying these ASOs in the brain. Better
design algorithms, which take LNA–protein interactions into
account during the ASO design stage, may be able to minimize
these off-target effects, but they still remain the biggest hurdle
to wide-spread use of LNA-based gapmers in general and in
neuroscience in particular (Koch et al., 2014). Nonetheless,
MOE-based gapmers have already demonstrated huge potential
for in vivo brain research and solidified the gapmer strategy as
the best method for future use of ASOs in vivo.
USE OF MORPHOLINOS TO REGULATE
GENE EXPRESSION IN THE BRAIN
In contrast to ASOs, which take advantage of modifications of
the ribose/deoxyribose sugar moiety or phosphodiester bonds
as key strategies for improving their stability, morpholinos
use a completely synthetic backbone (Summerton and Weller,
1997; Summerton et al., 1997). Morpholinos are oligomers that
replace the ribose/deoxyribose sugar ring with a six-member
morpholine, which is attached to other morpholines though
a non-ionic phosphorodiamidate linkage, which contrasts with
the charged phosphodiester bond found in typical ASOs. Each
morpholine ring is attached to a base (A,G,C,T), which is free
to form normal Watson–Crick base pairs with a target. The
exotic backbone of phosphorodiamidate morpholinos oligomer
(PMO) prevents it from being recognized and degraded by
normal nucleases, allowing the PMO to remain active for long
periods of time. As PMOs have such an exotic backbone, they
are not recognized as DNA and fail to recruit RNase H upon
biding with their target mRNA. However, as with non-gapmer
ASOs discussed previously, PMOs can still achieve knockdown
by interfering with splicing, translation, and miRNAmaturation.
As the phosphorodiamidate bonds in morpholinos do not
have a charge, PMOs cannot access the cytoplasm unassisted and
require an agent to facilitate their entry. However, the overall
uncharged nature of PMOs has also aided their use, in that
they show little interaction with cellular proteins and do not
appear to elicit an immune response (Moulton, 2013). Despite
the general inability to cross cell membranes, PMOs do exhibit
unassisted crossing of cell membranes in vivo in themousemodel
of Duchenne muscular dystrophy, in which cellular membranes
are already porous (Ezzat et al., 2015). In this instance, PMOs had
a therapeutic effect by causing translational skipping of the Dmd
transcript, restoring some level of Dmd function. However, the
inability to cross cell membranes has impeded the use of PMOs
outside of this specialized disease, thus limiting their widespread
use in modulating genes in vivo.
In order to address this limitation, vivo-Morpholinos
were developed, which consist of a terminal octaguanidinium
dendrimer linked to the PMO (Morcos et al., 2008; Reissner et al.,
2012). In addition, PPMOs were also developed, which contain
cell-penetrating peptides linked to PMO (Stone et al., 2008).
Although both modifications are designed to improve PMO
uptake into the cytoplasm, vivo-Morpholinos have shown utility
for in vivo brain work (Nizzardo et al., 2014). vivo-Morpholinos
link the PMO to a large octaguanidinium dendrimer, which
results in high cell permeability without reported losses in
activity. Many studies have examined the effects of IV or IP
injections of the vivo-Morpholino and have demonstrated robust
inhibition of gene activity (Ferguson et al., 2013; Subbotina
et al., 2016). However, uptake of systemically delivered vivo-
Morpholinos in the brain is much more restricted than in other
tissues (Li and Morcos, 2008; Morcos et al., 2008; Parra et al.,
2011; Moulton, 2013). Uptake can be dramatically improved
by directly injecting vivo-Morpholinos into brain regions of
interest, thus bypassing the blood–brain barrier and achieving
robust suppression of genes for up to 14 days after injection
(Oh et al., 2006; Reissner et al., 2012). Importantly, gene
suppression was achieved with a relatively low dose of vivo-
Morpholino (30 pmol), which is significantly below any dose
with demonstrated cytotoxic effects (1500 pmol; Reissner et al.,
2012).
vivo-Morpholinos and gapmer-based ASOs are the first
genetic tools thatmatch upwith themajor advantage of chemical-
based antagonists, largely based on their capacity for direct
application to a target area without requiring mouse models or
viral vectors to achieve knockdown. In addition, ASOs and vivo-
Morpholinos can be targeted at virtually every transcript and
can be designed to accomplish specific tasks, whether that be
mRNA degradation, translational inhibition, exon skipping, or
inhibiting miRNA processing, a feature that was never available
with chemical-based antagonists.
CONCLUSION
In recent years, we have seen the development of a wide
variety of extremely exciting and highly flexible gene editing
approaches that provide entirely new tools for studying gene
function in the brain. Here, we highlighted CRISPR/Cas9-based
approaches, which offer nearly unlimited flexibility, rapid, and
effective targeting of single genes, as well as the ability to target
multiple genes simultaneously. Combined with the plethora of
available modifications for this system, CRISPR/Cas9 is the
most flexible gene editing tool available today. In addition, anti-
sense mRNA inhibition is a simple method for obtaining rapid
knockdown of a target gene without requiring a viral delivery
system, making this approach highly accessible to virtually any
lab environment. These two approaches bring powerful new
methods into the hands of neuroscientists, providing important
tools for answering complex questions regarding gene–behavior
relationships in the brain.
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